Chen Huiwei, Yang Guang, Long Yunzhu, Li Chaoqian
Department of Emergency, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Qingxiu District, Nanning, Guangxi 530021, China.
Zhuzhou Central Hospital, ZhuZhou, Hunan 412000, China.
Evid Based Complement Alternat Med. 2021 Dec 20;2021:5582908. doi: 10.1155/2021/5582908. eCollection 2021.
To systematically evaluate the value of lymphocytes, platelets, and interleukin-6 in predicting the mortality of patients with coronavirus disease 2019 (COVID-19) and to provide medical evidence for the long-term prognosis of patients with COVID-19.
The latest studies published until July 1, 2021, were retrieved from databases including PubMed, Embase, and Cochrane Library to analyze the ability of lymphocyte and platelet counts as well as interleukin-6 levels to predict mortality in patients with COVID-19. Two reviewers independently screened the literature and extracted data, then evaluated the risk of bias of included studies using the Newcastle-Ottawa Scale (NOS), and used Stata 15.0 software for meta-analysis.
A total of nine studies were included, involving 4340 patients. There were 1330 patients in the death group and 3010 patients in the survival group. Meta-analysis showed that, compared with the survival group, lymphocyte counts in the death group were significantly lower (SMD = -0.64, 95% CI: -0.86--0.43, < 0.01), platelet counts were significantly lower (SMD = -0.47, 95% CI: -0.67--0.27, < 0.01), and interleukin-6 levels were significantly higher (SMD = 1.07, 95% CI: 0.62-1.53, < 0.01).
Lymphocyte and platelet counts, as well as interleukin-6 levels, can help predict the mortality of patients with COVID-19. Due to the limitation of the number and quality of the included studies, these conclusions need to be validated by additional high-quality studies.
系统评价淋巴细胞、血小板及白细胞介素-6对预测2019冠状病毒病（COVID-19）患者死亡率的价值，为COVID-19患者的远期预后提供医学依据。
检索截至2021年7月1日发表的最新研究，这些研究来自PubMed、Embase和Cochrane图书馆等数据库，以分析淋巴细胞计数、血小板计数及白细胞介素-6水平预测COVID-19患者死亡率的能力。两名研究者独立筛选文献并提取数据，然后使用纽卡斯尔-渥太华量表（NOS）评估纳入研究的偏倚风险，并使用Stata 15.0软件进行荟萃分析。
共纳入9项研究，涉及4340例患者。死亡组1330例，存活组3010例。荟萃分析显示，与存活组相比，死亡组淋巴细胞计数显著降低（标准化均数差[SMD]=-0.64，95%置信区间[CI]：-0.86至-0.43，P<0.01），血小板计数显著降低（SMD=-0.47，95%CI：-0.67至-0.27，P<0.01），白细胞介素-6水平显著升高（SMD=1.07，95%CI：0.62至1.53，P<0.01）。
淋巴细胞计数、血小板计数及白细胞介素-6水平有助于预测COVID-19患者的死亡率。由于纳入研究的数量和质量有限，这些结论需要更多高质量研究进行验证。
